# Official Website: Sethera Therapeutics

**Type:** source
**Status:** Useful
**Confidence:** Medium
**Source Type:** Official Website
**URL:** https://setheratx.com
**Publisher:** Sethera Therapeutics
**Accessed:** 2026-06-19
**Updated:** 2026-06-19

## Summary

Sethera Therapeutics' official website describes an enzymatic peptide cross-linking platform for synthesizing stable polymacrocyclic peptides (pMCPs), with partner-facing discovery capabilities and a Salt Lake City office.

## Useful Claims

- The site positions Sethera around enzymatic peptide cross-linking technology for stable, polymacrocyclic peptide therapeutics.
- Sethera offers a PolyMacrocyclic peptide (pMCP) Discovery Platform for partners to discover and engineer macrocyclic peptides with diverse architectures and chemistries.
- Platform capabilities described include enzymatic library creation, hit identification, tuning with noncanonical building blocks, and modular polymacrocyclic recombination.
- The cyclization enzyme is said to recognize programmable sequence motifs to site-specifically install thioether bonds, potentially multiple times per molecule.
- The approach is described as compatible with phage, mRNA display, and DNA-encoded library screening methods.
- Sethera states it is seeking partners to leverage its peptide architectures for target screening and drug discovery collaborations.
- Office address listed: 48 S Rio Grande St, Salt Lake City, UT 84101.

## Reliability Notes

This is an official company source. It is useful for platform positioning, enzymatic-mechanism claims, and partnership intent, but generalization across peptide targets, clinical-candidate status, and in-vivo validation should be cross-checked with peer-reviewed publications and independent technical sources before being treated as high-confidence evidence.

## Related Pages

- [Sethera Therapeutics](sethera-therapeutics.md)

## See Also

- [Sethera team page](https://setheratx.com/sethera-team/) — leadership and advisory board listed on the official site